Gemzen Injection 200 mg/5.26 ml contains Gemcitabine, a widely used anticancer medication belonging to the antimetabolite class. It is formulated as a sterile intravenous injection and is commonly included in chemotherapy regimens for the treatment of various solid tumors. Gemzen Injection is administered under strict medical supervision in specialized oncology settings to ensure safety and optimal therapeutic outcomes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active Ingredient: Gemcitabine 200 mg per 5.26 ml injection

Therapeutic Class

• Antineoplastic agent

• Pyrimidine antimetabolite

Indications

Gemzen Injection is indicated for the treatment of several types of cancer, including:

• Non-small cell lung cancer

• Pancreatic cancer

• Breast cancer

• Ovarian cancer

• Bladder cancer

Depending on the clinical condition, it may be used alone or in combination with other chemotherapeutic agents.

Mechanism of Action

Gemcitabine is a nucleoside analogue structurally related to deoxycytidine. Once administered intravenously, it is taken up by cells and converted into active diphosphate and triphosphate metabolites. These active forms inhibit ribonucleotide reductase and interfere with DNA synthesis by incorporating into the DNA strand. This dual action leads to inhibition of tumor cell proliferation and induces cell death, making gemcitabine effective against rapidly dividing cancer cells.

Dosage and Administration

• Gemzen Injection is given by intravenous infusion, typically over 30 minutes.

• The exact dosage and treatment schedule depend on the type of cancer, body surface area, combination therapy, and patient response.

• Administration should only be performed by trained healthcare professionals experienced in chemotherapy.

Regular monitoring of blood counts and organ function is essential throughout the treatment period.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Use in Special Populations

• Elderly Patients: Careful dose selection and monitoring are recommended.

• Hepatic and Renal Impairment: Use with caution and adjust dose as necessary.

• Pregnancy and Breastfeeding: Gemcitabine is contraindicated due to potential risk to the fetus or infant.

Side Effects

Patients receiving Gemzen Injection may experience:

• Myelosuppression, including neutropenia and thrombocytopenia

• Nausea and vomiting

• Fatigue and general weakness

• Fever and flu-like symptoms

• Elevated liver enzymes

• Skin reactions such as rash or itching

Most side effects are dose-related and reversible with appropriate management.

Drug Interactions

Gemcitabine may interact with:

• Other cytotoxic drugs, increasing toxicity

• Radiotherapy, which may enhance adverse reactions

• Live vaccines, which should be avoided during treatment

Patients should inform their healthcare provider of all medications before starting therapy.

Storage

• Store according to manufacturer’s recommendations

• Protect from light

• Keep out of reach of children

• Do not freeze unless otherwise instructed

Advantages of Gemzen Injection

• Effective against a wide range of solid tumors

• Suitable for flexible dosing and combination therapy

• Well-established efficacy and safety profile in oncology practice

• Available in lower strength for dose customization.